John Munkhaugen
Overview
Explore the profile of John Munkhaugen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pivoriunas J, Engebretsen I, Vethe N, Kristiansen O, Dammen T, Husebye E, et al.
Atherosclerosis
. 2025 Mar;
403:119138.
PMID: 40056690
Background And Aims: An accurate and feasible method to assess adherence to statin therapy is needed. We developed a novel blood test to identify reduced statin adherence and compared statin...
2.
Engebretsen I, Odegaard K, Halvorsen S, Bugge C, Kristiansen I, Stovring H, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Nov;
PMID: 39562279
Aims: Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) are recommended for high-risk patients if the low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statins and ezetimibe. We...
3.
Ihle-Hansen H, Ihle-Hansen H, Rostoft S, Munkhaugen J, Westbye S, Romoren M, et al.
Tidsskr Nor Laegeforen
. 2024 Nov;
144(13).
PMID: 39498650
Background: New national clinical guidelines are now available on advance care planning (ACP). Confidence in communication is important for implementation of the guidelines. This study aims to identify healthcare personnel's...
4.
Lauritzen T, Munkhaugen J, Bergan S, Sverre E, Peersen K, Lindahl S, et al.
Clin Transl Sci
. 2024 Oct;
17(10):e70025.
PMID: 39444168
Statin-associated muscle symptoms are frequently reported and often lead to discontinuation of statin therapy with an increased risk of cardiovascular events. In vitro studies suggest that statin-mediated inhibition of the...
5.
Atar D, Munkhaugen J, Sverre E
Kardiol Pol
. 2024 Sep;
82(9):828-830.
PMID: 39240921
No abstract available.
6.
Otterstad J, Munkhaugen J, Ruddox V, Edvardsen T, Hjelmesaeth J
Scand Cardiovasc J
. 2024 Aug;
58(1):2386984.
PMID: 39106197
To investigate whether normal body mass index (BMI) shortly after percutaneous coronary intervention (PCI) for myocardial infarction is associated with increased risk of long-term major cardiovascular events (MACE), and to...
7.
Pleym K, Dammen T, Wedon-Fekjaer H, Husebye E, Sverre E, Tonstad S, et al.
Eur Heart J Open
. 2024 Apr;
4(2):oeae028.
PMID: 38666249
Aims: To evaluate the effects of a multi-component intervention for smokers hospitalized for atherosclerotic cardiovascular disease (ASCVD) on the participation rate in community-based cessation programmes and the use of cessation...
8.
Engebretsen I, Bugge C, Stovring H, Husebye E, Sverre E, Dammen T, et al.
Atherosclerosis
. 2024 Apr;
393:117550.
PMID: 38657552
Background And Aims: Proper prescription and high adherence to intensive lipid lowering drugs (LLD) in patients with coronary heart disease (CHD) are crucial and strongly recommended. The aim of this...
9.
Lauritzen T, Munkhaugen J, Bergan S, Peersen K, Svarstad A, Andersen A, et al.
Atheroscler Plus
. 2024 Jan;
55:31-38.
PMID: 38293288
Background And Aims: Statin-associated muscle symptoms (SAMS) is a prevalent cause of statin discontinuation. It is challenging and time-consuming for clinicians to assess whether symptoms are caused by the statin...
10.
Pivoriunas J, Vethe N, Husebye E, Fagerland M, Bergan S, Kristiansen O, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Jan;
10(4):307-315.
PMID: 38196131
Aims: Objective methods to determine statin adherence are requested to improve lipid management. We have recently established a method to detect reduced adherence to atorvastatin therapy with cut-off values based...